BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 125273
Published online Nov 15, 2026. doi: 10.4251/wjgo.125273
Table 2 A summary of tissue-based biomarkers identified in ulcerative colitis-colorectal cancer and their clinical relevance for screening
Biomarker
Clinical relevance
Advantages/limitations
Ref.
TP5371% in low-grade dysplasia, 83% in high-grade dysplasia, 100% in adenocarcinoma; absent in uninvolved mucosaAdjunctive biomarker to identify high-risk patients before histologic changes occur, predicting risk of evolution toward malignancy[88,138-140]
p14ARF hypermethylation100% in dysplastic tissue vs 26% in non-dysplastic biopsiesPredictor of future dysplasia during surveillance[141,142]
1-8U gene (interferon-inducible) (IFITM3)High expression in cancer and severely inflamed and cancerous UC mucosa; absent in normal tissueDiscrimination of high-risk areas before visible dysplasia[143,144]
Telomere shortening + clonal expansions100% sensitivity, 80% specificity distinguishing progressors from non-progressors (early-onset UC)Risk stratification in young patients with extensive disease[145,146]
Associated with proximity to dysplasia
Aneuploidy (flow cytometry ploidy)5/6 patients with aneuploidy developed dysplasia in 1-2.5 years vs 0/19 without aneuploidyNot routinely implemented by insufficient prospective validation, and the growing emphasis on gene-specific genomic alterations[88,146-148]
Adjunctive marker in biopsies indefinite for dysplasia
Copy number variants (lpWGS-derived CNA score)Cumulative chromosomal alterations before advanced neoplasiaScalable, cost-effective tool to predict progression from low-grade dysplasia[88,149,150]
Lack of prospective multicenter validation, standardized analytical pipelines and cut-off values, and generalizability beyond low-grade dysplasia cohorts
miR-9 methylationIncreases with age, disease duration, proximity to cancerHigh-accuracy discrimination in rectal mucosa
Lack of independent prospective validation and evidence supporting its use only within multi-marker methylation panels
[88,151,152]
Methylation panel (SFRP2, SFRP4, WIF1, APC1A, APC2)Detects pre-cancerous and invasive neoplasiaValidated multiplex panel from a multicenter study (ENDCAP-C)
Limited by the need for colonic biopsy, only moderate prediction of neoplastic progression in non-neoplastic mucosa, and the transition toward genome-wide biomarkers (e.g., CNA profiling and lpWGS)
[153,154]
Stool microbiome
(16 rRNA sequencing)
Mucosal microbiota (Firmicutes/Bacteroidetes ratio) exhibit persistent dysbiosis UC-CRCPositive association between Fermicutes and Proteobacteria Bacteroidetes and inflammatory markers with incidence of CRC[155,156]
TP53-nuclear (IHC) + cytokeratin 7TP53 strong nuclear overexpression correlates with neoplastic progressionUseful adjunct when histology is ambiguous (indefinite for dysplasia)[157-159]
CK7 not expressed in normal colonic mucosa. Expressed in all cases of epithelial dysplasia, with no difference between moderate and severe dysplasia
miR-21, miR126, miR146b-5p and miR-223Upregulation in active UCNon-invasive disease monitoring[160]
miR-142-3p, miR-144-3p, and miR-193a-5pOverexpression in adenomas but down-regulated in CRCBiomarker pre-cancer[161]
miR-31, miR-135b and miR-106aTracking of malignant progression via expression profilingMucosal miRNAs that not only accurately discriminate dysplasia from normal mucosa but also indicate a higher risk of CRC and are expressed in UC-CRC[162,163]
ctDNA, circulating tumor cells, exosomes, tumor-educated plateletsReflect real-time molecular heterogeneityMinimally invasive surveillance complementary to colonoscopy[164]
Requires validation
KRAS mutationsOccur later, often co-occurring with TP53
Frequency of KRAS mutations increases continuously from non-dysplastic IBD colon to UC-CRC, and they are observed to be mutually exclusive with BRAF mutations
Limited clinical utility as a standalone biomarker[165]
Invisible lesions in patients without IBD exhibit fewer KRAS and APC mutations compared with polypoid lesions, but show a higher frequency of BRAF mutationsKRAS mutations were enriched in non-dysplastic UC colon at approximately 14%[166]


Write to the Help Desk